Comparative Pharmacology
Head-to-head clinical analysis: ACTOPLUS MET XR versus ROSIGLITAZONE MALEATE AND GLIMEPIRIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTOPLUS MET XR versus ROSIGLITAZONE MALEATE AND GLIMEPIRIDE.
ACTOPLUS MET XR vs ROSIGLITAZONE MALEATE AND GLIMEPIRIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTOPLUS MET XR combines pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating PPAR-γ, and metformin, a biguanide that decreases hepatic glucose production and improves peripheral glucose uptake.
Rosiglitazone is a thiazolidinedione that acts as an agonist at peroxisome proliferator-activated receptor gamma (PPARγ), increasing insulin sensitivity in adipose tissue, skeletal muscle, and liver. Glimepiride is a sulfonylurea that stimulates insulin release from pancreatic beta cells by blocking ATP-sensitive potassium channels.
Initial dose: 15 mg pioglitazone/500 mg metformin hydrochloride extended-release orally once daily with evening meal. Titrate based on glycemic response, maximum dose 45 mg pioglitazone/2000 mg metformin hydrochloride extended-release per day.
Oral, initial dose 4 mg rosiglitazone/1 mg glimepiride once daily, titrate based on glycemic response; maximum dose 8 mg rosiglitazone/4 mg glimepiride once daily.
None Documented
None Documented
Pioglitazone: terminal half-life 3-7 hours (parent), 16-24 hours (active metabolites); clinical effect sustained due to metabolites. Metformin: terminal half-life 6.2 hours (plasma), elimination prolonged in renal impairment (creatinine clearance <60 mL/min).
Rosiglitazone: 3-4 hours. Glimepiride: 5-9 hours. Clinically, twice-daily dosing for rosiglitazone and once-daily for glimepiride.
Pioglitazone: predominantly hepatic metabolism, 15-30% excreted in urine as metabolites, ~20% in feces. Metformin: 90% renal excretion unchanged via glomerular filtration and tubular secretion.
Rosiglitazone: primarily hepatic metabolism with <1% excreted unchanged in urine; fecal (23%) and urinary (64%) elimination as metabolites. Glimepiride: ~60% excreted in urine as metabolites, ~40% in feces as metabolites.
Category C
Category A/B
Thiazolidinedione/Biguanide Combination
Thiazolidinedione